7-溴-2,4-二氨基喹唑啉 | 137553-43-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 7-溴-2,4-二氨基喹唑啉
• 中文别名: 2,4-二氨基-7-溴喹唑啉
• 英文名称: 7-bromo-2,4-diaminoquinazoline
• 英文别名: 7-bromoquinazoline-2,4-amine；7-bromo-quinazoline-2,4-diamine；7-bromoquinazoline-2,4-diamine
• CAS: 137553-43-6
• 化学式: C₈H₇BrN₄
• 分子量: 239.074
• InChiKey: YPWBLOIRVSSESG-UHFFFAOYSA-N

物化性质

• 沸点：
  509.4±58.0 °C(Predicted)
• 密度：
  1.828±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 7-Bromo-2,4-diaminoquinazoline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 7-Bromo-2,4-diaminoquinazoline
CAS number: 137553-43-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H7BrN4
Molecular weight: 239.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-溴-2,4-二氨基喹唑啉 在 盐酸 、 palladium diacetate 、 caesium carbonate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 生成 7-(Aminomethyl)quinazoline-2,4-diamine
  参考文献：
  名称：

  [EN] PRMT5 INHIBITOR COMPOUNDS
  [FR] COMPOSÉS INHIBITEURS DE LA PRMT5

  摘要：

  本文介绍了一系列PRMT5抑制剂化合物。这些化合物可用作PRMT5抑制剂化合物，并用于治疗PRMT5介导的疾病、紊乱和其症状。

  公开号：

  WO2020205660A1
• 作为产物：
  描述：

  4-溴-2-氟苯胺 在 盐酸 、 copper(l) chloride 、 sodium nitrite 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 18.83h， 生成 7-溴-2,4-二氨基喹唑啉
  参考文献：
  名称：

  Hynes, John B.; Tomazic, Alenka; Parrish, Christie A., Journal of Heterocyclic Chemistry, 1991, vol. 28, # 5, p. 1357 - 1364

  摘要：

  DOI：

文献信息

• Quinazoline protein tyrosine phosphatase inhibitors
  申请人：Berthel Joseph Steven

  公开号：US20060211715A1

  公开（公告）日：2006-09-21

  The present invention comprises aminoquinazoline compounds of the general formula I: wherein X is an unsubstituted or substituted phenyl, or is an unsubstituted or substituted 5 or 6 membered heteroaromatic ring. The compounds of the present invention are potent inhibitors of PTP1B. Accordingly, the invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.

  本发明涵盖通式I的氨基喹唑啉化合物：其中X是未取代或取代的苯基，或未取代或取代的5或6元杂环芳香族环。本发明的化合物是PTP1B的有效抑制剂。因此，本发明还包括治疗或预防PTP-1B介导的疾病，包括糖尿病、肥胖症和糖尿病相关疾病的药物组合物和方法。
• Quinazoline Protein Tyrosine Phosphatase Inhibitors
  申请人：Berthel Steven Joseph

  公开号：US20090105477A1

  公开（公告）日：2009-04-23

  The present invention comprises aminoquinazoline compounds of the general formula I: wherein X is an unsubstituted or substituted phenyl, or is an unsubstituted or substituted 5 or 6 membered heteroaromatic ring. The compounds of the present invention are potent inhibitors of PTP1B. Accordingly, the invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.

  本发明涉及一种一般式I的氨基喹唑啉化合物:其中X是未取代或取代的苯基，或未取代或取代的5或6元杂环芳香环。本发明的化合物是PTP1B的有效抑制剂。因此，本发明还包括制备药物组合物和治疗或预防PTP-1B介导的疾病，包括糖尿病，肥胖症和糖尿病相关疾病的方法。
• [EN] BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5<br/>[FR] INHIBITEURS HÉTÉROAROMATIQUES BICYCLIQUES DE LA KLK5
  申请人：BIOCRYST PHARM INC

  公开号：WO2022221526A1

  公开（公告）日：2022-10-20

  Disclosed are compounds of formulae (I) - (IV), and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein-related peptidase 5 (KLK5). Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant KLK5 activity activity, such as Netherton Syndrome.

  本发明涉及式(I)-(IV)的化合物及其药学上可接受的盐，这些化合物是卡利肯酶相关肽酶5（KLK5）的抑制剂。还提供了包含这种化合物的制药组合物以及使用这些化合物和组合物治疗或预防由异常KLK5活性引起的疾病或病状的方法，例如Netherton综合症。
• [EN] KHK INHIBITORS<br/>[FR] INHIBITEURS DE KHK
  申请人：GILEAD SCIENCES INC

  公开号：WO2022212194A1

  公开（公告）日：2022-10-06

  Compounds of formula (I), wherein the variable substituents are defined herein.

  式(I)的化合物，其中变量取代基在此定义。
• [EN] NITROGEN-CONTAINING RING-FUSED COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] COMPOSÉ À CYCLES CONDENSÉS CONTENANT DE L'AZOTE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 含氮并环化合物、其制备方法及用途
  申请人：SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD

  公开号：WO2021114691A1

  公开（公告）日：2021-06-17

  本发明涉及含氮并环化合物、其制备方法及用途。具体而言，本发明涉及具有式(X)所示结构的化合物，所述化合物的立体异构体、互变异构体或其混合物，所述化合物的药学上可接受的盐、共晶、多晶型物或溶剂合物，或者所述化合物的稳定同位素衍生物、代谢物或前药。本发明的化合物可以具有式(I)或式(III)所示结构。这些化合物可用于细胞增殖异常性疾病(例如癌症)的治疗。